CORE--COLON ONCOLOGY

核心设施-结肠肿瘤学包括在名为：‘DNA’的项目中 结肠癌的拓扑异构酶I靶向治疗。组织储存库 (人体组织带)，这是设施的一部分，是必不可少的 该提案的目标如下： 1.选择结肠腺癌患者，获取其 用于实验室研究的病理和正常结肠组织。 2.维持人类组织库作为临床材料的来源 DNA拓扑异构酶I的分子、细胞和肿瘤生物学研究 3.组织患者数据库，用于关联 实验室和临床结果。 该项目的这一部分已经启动，并取得了 调查报告在初步研究项下进行。整体而言 目标将在02支助年度结束时实现。在02年- 03，将实现另外两个目标： 4.为美国食品研究新药(IND)申请做准备 和药品管理局。申请将以项目研究为基础 一种或几种领先的类似物，以及毒理学和 本项目外独立完成的药理学研究。 5.为Leader的初步临床研究准备一期方案 类比(S)在工程中发现。

CORE FACILITY-COLON ONCOLOGY is included in the project entitled: 'DNA Topoisomerase I-Targeted Therapy of Colonic Cancer'. A tissue depository ('Human Tissue Band"), which is part of the facility, is essential for the following aims of the Proposal: 1. To select patients with adenocarcinoma of the colon and obtain their pathologic and normal colonic tissues for laboratory studies. 2. To maintain the Human Tissue Bank as a source of clinical material for research on molecular, cellular and tumor biology of DNA topoisomerase I. 3. To organize a patient data base, which will be used to correlate laboratory and clinical findings. This part of the project has been initiated, and the results of investigations are reported under Preliminary Studies. The overall objectives will be met by the end of the 02 year of support. In year 02- 03, two additional objectives will be accomplished: 4. To prepare the Investigational New Drug (IND) application to the US Food and Drug Administration. The application will be based on Project studies of one or several leading analogs, as well as on toxicology and pharmacology research done independently outside this Project. 5. To prepare a Phase-I protocol for initial clinical research of leading analog(s) discovered in the Project.